ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022
Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Stigmatizing language in alcohol-associated cirrhosis open notes: Persistent but declining.Hepatology communications · 2026Article
- Impact of Evolving Evidence on Pharmacological Therapy for Alcohol-Associated Hepatitis in Alberta: A Population-Based Study of Practice Trends and MELD-Stratified Effectiveness of Corticosteroids.Alimentary pharmacology & therapeutics · 2026Article
- Bridging Critically Ill Patients With Cirrhosis to Transplant With Renal Replacement Therapy: A Multicenter Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- Navigating Care Amid Crisis: The Impact of the COVID-19 Pandemic on Eosinophilic Esophagitis Management in Canada.Journal of clinical medicine · 2025Article
- Persisting challenges in the early detection of hepatocellular carcinoma.Expert review of anticancer therapy · 2025Review
- Alcohol-associated hepatitis trends before and following the onset of the COVID-19 pandemic across two distinct cohorts in the United States and Hong Kong.JHEP reports : innovation in hepatology · 2025Article
- Epidemiology and Outcomes of Alcohol-Associated Hepatitis in Adolescents and Young Adults.JAMA network open · 2024Article
- Risk of mortality among patients with alcohol-associated hepatitis in the US from 2007 to 2021.Alcohol (Fayetteville, N.Y.) · 2024Article
- Quality standards on management of alcohol-related liver disease from the UK-targets and tribulations.Hepatobiliary surgery and nutrition · 2024Article
- Impact of the COVID-19 pandemic on the incidence and type of infections in hospitalized patients with cirrhosis: a retrospective study.Scientific reports · 2024Article
- Emergency services utilization by patients with alcohol-associated hepatitis: An analysis of national trends.Alcohol, clinical & experimental research · 2024Article
- Fuel to the fire: The impact of COVID-19 on alcohol-associated hepatitis.Alcohol, clinical & experimental research · 2023Article
- Mortality Increased Among Hospitalized Patients with Cirrhosis Before and Following Different Waves of the COVID-19 Pandemic.Digestive diseases and sciences · 2023Article
- Epidemiology and trends of alcohol use disorder and alcohol-associated liver disease.Clinical liver disease · 2023Review
- Comment on: Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States.Journal of hepatology · 2023Article
- COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations.World journal of hepatology · 2023Review
- Therapeutic Pipeline in Alcohol-Associated Liver Disease.Seminars in liver disease · 2023Review
- COVID-19 Alcoholic Cirrhosis and Non-Alcoholic Steatohepatitis Cirrhosis Outcomes among Hospitalized Patients in the United States: Insight from National Inpatient Sample Database.Tropical medicine and infectious disease · 2022Article
- Covid-19 and alcohol associated liver disease.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2022Review
- Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.Journal of hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsCoronavirus disease 2019 (COVID-19) pandemic lockdown and restrictions had significant disruption to patient care. We aimed to evaluate the impact of COVID-19 restrictions on hospitalizations of patients with alcoholic and nonalcoholic cirrhosis as well as alcoholic hepatitis (AH) in Alberta, Canada.
methodsWe used validated International Classification of Diseases (ICD-9 and ICD-10) coding algorithms to identify liver-related hospitalizations for nonalcoholic cirrhosis, alcoholic cirrhosis, and AH in the province of Alberta between March 2018 and September 2020. We used the provincial inpatient discharge and laboratory databases to identify our cohorts. We used elevated alanine aminotransferase or aspartate aminotransferase, elevated international normalized ratio, or bilirubin to identify AH patients. We compared COVID-19 restrictions (April-September 2020) with prior study periods. Joinpoint regression was used to evaluate the temporal trends among the 3 cohorts.
resultsWe identified 2916 hospitalizations for nonalcoholic cirrhosis, 2318 hospitalizations for alcoholic cirrhosis, and 1408 AH hospitalizations during our study time. The in-hospital mortality rate was stable in relation to the pandemic for alcoholic cirrhosis and AH. However, nonalcoholic cirrhosis patients had lower in-hospital mortality rate after March 2020 (8.5% vs 11.5%; P = .033). There was a significant increase in average monthly admissions in the AH cohort (22.1/10,000 admissions during the pandemic vs 11.6/10,000 admissions before March 2020; P < .001).
conclusionsBefore and during COVID-19 monthly admission rates were stable for nonalcoholic and alcoholic cirrhosis; however, there was a significant increase in AH admissions. Because alcohol sales surged during the pandemic, future impact on alcoholic liver disease could be detrimental.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.